Background and Objectives: Genome Wide Association Studies (GWAS) have
| INTRODUCTION
Asthma affects over 350 million people world-wide, with high prevalence in both pediatric and adult populations. 1 Responsiveness to asthma medications significantly impacts quality of life for most individuals with asthma. Genome wide association studies (GWAS) have sought to identify genetic variants that predict asthma treatment response, with precision medicine (individualized treatment tailored by genotype) 2 as the ultimate goal. These studies may combine pediatric and adult populations, with little to no emphasis on the potential role of age in modifying the impact of genetic variants on asthma treatment response. Age may be an important modifier of pharmacogenetic associations, especially since age-related differences in asthma phenotypes may reflect different underlying pathogenic pathways, 3 the genetic variation in which may also affect asthma treatment response. In other words, the genetic polymorphisms with utility for predicting asthma treatment responses may change along with agerelated changes in asthma phenotype. The identification of age-related asthma phenotypes is not new; clinicians have long understood that childhood asthma tends to be dominated by Th2 mediated responses and eosinophilia, while adult asthma phenotypes are more heterogeneous, and can be either Th2 mediated/eosinophilic, neutrophilic, or obesity-related. 4 One of the most widely used asthma medications in both child and adult populations is albuterol, a short-term β 2 -agonist that serves as a bronchodilator. β 2 -agonists promote bronchodilation by stimulating β 2 adrenergic receptors on airway smooth muscle cells to reduce bronchoconstriction via downstream increases in cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). 5 Bronchodilator response (BDR) to albuterol as an asthma phenotype involves inflammation and interactions among multiple airway cell types including the epithelium, 6 smooth muscle cells 7 and cells of the autonomic nervous system. 8 GWAS studies have identified genetic polymorphisms associated with BDR. [9] [10] [11] Thus far, the impact of these genetic variants on longitudinal changes in BDR from childhood to adulthood in individuals with asthma has not been examined. In this study, our aim was to test GWAS polymorphisms associated with BDR for effect modification by age in the Childhood Asthma Management
Program (CAMP) clinical trial which has genome-wide polymorphism data and longitudinal bronchodilator response outcomes from early childhood to young adulthood (ages 5-30).
2 | METHODS
| CAMP study design and participants
CAMP was a randomized, placebo-controlled trial of budesonide, nedocromil, or placebo for mild-to-moderate childhood asthma followed by three phases of observational follow-up; the trial and all follow-up phases included pre-bronchodilator and post-bronchodilator spirometry. 12 A total of 1041 children, 5-12 years of age, were enrolled in the trial between December 1993 and September 1995. 12 Inclusion was restricted to children with a history of chronic asthma who, during a 28-day run-in period, had asthma symptoms or a low morning peak flow on eight or more days; inclusion also required a methacholine challenge with a concentration of 12.5 mg/mL or less that resulted in a reduction in FEV 1 by at least 20% (since airway responsiveness is determined by the provocative concentration of methacholine required to reduce the FEV1 by at least 20% [methacho-
line PC20], with higher values indicating less airway responsiveness).
Approval was obtained from the institutional review boards at each of the CAMP-participating institutions before initiation of the trial.
Informed consent was obtained from the parent or guardian of the participant, and the child's assent was obtained before study enrollment.
Participants were randomly assigned to receive budesonide, nedocromil, or placebo, all by inhalation. Treatment was continued for a mean of 4.5 years (participants attended three clinical trial "visits"
per year). The treatment component of the trial ended in 1999, and asthma care was transferred to each participants' health care provider.
Over 85% of the original 1041 participants participated in the 4 month transition phase (2 visits) following the trial, and 80% participated in all three phases (the treatment phase, the transition phase, and the continued follow-up phase [1-4 visits per year for 13 years]). 13 We considered subjects of white race/ethnicity for our longitudinal analysis. Of the original 1041 participants, 711 were white, and 604 white subjects had genotyping data. The 604 subjects included both 
| SNP selection and genotyping
We used the NHGRI-EBI (National Health Genome Research InstituteEuropean Bioinformatics Institute) catalog of published genome-wide association studies search tool (https://www.ebi.ac.uk/gwas/) to search for GWAS associations at a suggestive P-value threshold of ≤ 1 × 10 −5 . We conducted our search with the following search terms "asthma (bronchodilator response)" and "bronchodilator response in asthma." We identified four GWAS studies, three of which reported associations between genotypes and bronchodilator response. In these studies, four SNPs were associated with BDR.
9-11
These variants are shown in Table 1 , and include SNPs associated with 
| Statistical analysis
To assess the impact of age by genotype interactions on longitudinal BDR response, we used a mixed model approach (PROC MIXED) in SAS Statistical Software. Mixed models included main effects of age and additive genotype, a multiplicative interaction term (age x genotype), covariates (sex and treatment group), and random effects (subject specific intercept and slope). In additional models, we also adjusted for random effect of family (as a small number of children were siblings), but found that this made no difference in the results (see Supplement). Adjustment for the first six genotype principle components also did not change results in a meaningful way (see Supplement). For testing, we used the general linear mixed model with a compound symmetry covariance structure, since our data fit the model assumptions of this approach. (We also considered a first order auto-regressive covariance structure. We found that this model had a higher AIC than the compound symmetry model, therefore we used the compound symmetry covariance structure instead). For visualization, we used a generalized additive mixed model, due to the flexible nature of the linearity assumption.
For the generalized additive mixed model we used the gamm4 package in R, which allows for random effect of age, and a running smoother with no specified knots for the fixed effect of age. 3 | RESULTS
| CAMP demographics
In CAMP, the mean age of enrollment was 8.95 years (standard deviation [s.d.] ± 2.13). Characteristics of study subjects are shown in Table S1 . The mean age at asthma diagnosis in CAMP subjects was 3.08 years (s.d. ± 2.44). Sixty percent of subjects were male, and 25%
had a maternal history of asthma. Overall, the socioeconomic status of participants was relatively high; only 19% reported a household income level of less than $30 000 per year. We tested age by genotype interactions in white subjects (N = 604) only.
| BDR as a function of age
We examined the main effect of age on BDR response prior to testing for age by genotype interactions. BDR response consistently decreased with age, as is shown in Figure 1 . Visual investigation of the generalized additive mixed model (Figure 1 ) supports the linear assumption between age and BDR. On average, BDR decreased 0.24% with each increasing year of age (Table 2) . Treatment group and sex did not confound the association between age and BDR over time (Table 2) , and were not independent predictors of BDR. Since the CAMP longitudinal follow-up included the typical time period overlapping with the onset of puberty (which is later for males than females), we tested for interactions between age and sex, as a way of potentially accounting for sex-specific shifts in BDR that may occur as following puberty. Test of the interaction term for age × sex were non-significant (P = 0.13).
| Age by genotype interactions for longitudinal BDR
We tested age by genotype interactions for all four identified BDR GWAS variants in mixed models, and found that two of the four with age, such that genotype-specific BDR response curves appeared to converge in adolescence at approximately age 15 years. To test whether these variants had significant main effects or age by genotype interactions after this time point, we performed sensitivity analyses by re-analyzing our mixed models using repeated measures of BDR from age 15 onward (see Supplemental Table S2 ). In CAMP, the effect of the SPATS2L variant (T allele) and its interaction with age were no longer statistically significant, suggesting that SPATS2L genotype mainly predicts BDR response in childhood/early adolescence, and that its effects on BDR no longer vary by age once subjects reach SNPs, a large percentage of our study population (41%) had one or more minor alleles for these variants (T for rs295137 near SPATS2L
and C for rs2626393 near ASB3). Age-related changes in asthma phenotypes have been well documented, with marked shifts occurring after puberty. 14 The clinical trajectory of children with asthma typically shows improvement in asthma symptoms over time, a longitudinal trend most likely to occur in subjects with mild to moderate persistent asthma. 15 In fact, it is estimated that asthma symptoms persist from childhood to adulthood in approximately one third of cases. 16 Age-related changes in gene expression patterns may underlie these longitudinal changes in asthma phenotypes. Genomic studies in multiple tissue types have identified dramatic shifts in both the transcriptome 17 and the methylome 18 that occur with increasing age; however, the dearth of airway tissue samples in these studies makes it difficult to identify age related changes in the lung that may alter asthma phenotypes or treatment response. The relatively few studies to examine lung-specific endophenotypes 19 have related sputum cellularity to asthma treatment response, showing that cell types (ie, eosinophil vs neutrophil dominant) are more variable in adults and can be used to guide treatment response, 20 whereas cell types in children are not markedly different by severity status, and have yet to be proven a useful guide to treatment. 21, 22 The SPATS2L and ASB3 related polymorphisms associated with altered longitudinal bronchodilator responses are both biologically plausible modifiers of this lung function phenotype. In vitro functional experiments, published in conjunction with the BDR GWAS by Himes et al, 11 show that miRNA knockdown on the SPATS2L gene leads to increased β 2 adrenergic receptor expression, suggesting that this gene may be important for down regulation of β 2 adrenergic receptors. ASB3 expression appears to be effected by β 2 agonists, and is known to regulate differentiation in muscle cells. 23 GWAS hits in both of these genes emerged in combined cohort studies of both children and adults; however, the primary discovery populations for these polymorphisms contained two clinical trials in childhood subjects (CAMP, CARE), as well as other trials that were a mix of child, adolescent, and adult asthmatics (LOCCS, LODO, Sephracor, ACRN). We were unable to detect age modification of GWAS hits from the Duan et al 9 study, which included polymorphisms in the COL22A1 gene. Of the genes identified as GWAS hits in our NHGRI search, COL22A1 is the least biologically plausible hit, with little known about this gene, except that it may encode for a cell adhesion ligand for skin fibroblasts and epithelial cells.
The strongest feature of our study is the longitudinal BDR phenotype data on asthmatics, where the effects of age on BDR trajectory are observed for each individual subject. We observed effect modification of associations by age, even after adjusting for sex and treatment group, and were able to visualize non-linear trends with age through the use of repeated measures generalized additive modeling techniques. Although there were many strengths to our study, a few caveats deserve mention.
The CAMP study is unique in its extended, 16 year follow-up of asthmatic subjects and therefore we did not have access to a similar cohort for replication of our findings. We did not have Tanner stage assessment, which may have helped us tease apart age-related effects from those of pubertal onset. To optimize power, we focused only on GWAS hits for testing, but may have missed other important polymorphisms that interact with age to alter BDR. In addition, as with any analysis of BDR phenotypes, it is difficult to disentangle whether BDR shifts with age are due to alterations in treatment response to albuterol, or changes in asthma phenotype that reduce the baseline level of bronchoconstriction.
Moreover, by screening only GWAS hits we may have missed some relevant polymorphisms, especially given that the GWAS studies we drew from combined child and adult populations together (potentially obscuring life-stage specific genetic associations for BDR that we could have tested in our longitudinal models). Nevertheless, focusing our longitudinal analysis on GWAS polymorphisms associated with BDR proved to be an effective method for identifying possible age-related modification of genetic effects.
| CONCLUSIONS
In summary, our findings suggest that there are substantial biologic changes that occur in the airway as children age that may vary by genotype. These findings bear relevance for future precision medicine efforts, and suggest that genomic panels for identifying the most efficacious individualized treatment should rely on age-specific genomic makers.
